What is ClearPoint Neuro Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. ClearPoint Neuro's interest expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. ClearPoint Neuro's Operating Income for the
three
months ended in Dec. 2023 was $ -4.71 Mil. ClearPoint Neuro's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
GuruFocus does not calculate ClearPoint Neuro's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ClearPoint Neuro Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClearPoint Neuro (NAS:CLPT) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
ClearPoint Neuro's Interest Expense for the
three
months ended in Dec. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-4.71 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $13.52 Mil.
ClearPoint Neuro's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| GuruFocus does not calculate ClearPoint Neuro's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
ClearPoint Neuro (ClearPoint Neuro) Business Description
Traded in Other Exchanges
N/A
Address
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace is used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint neuro system, MRI-guided drug delivery, and Thermal therapy system.
Executives
| Lynnette C Fallon |
director |
108 CHERRY HILL DRIVE, BEVERLY MA 01915 |
| Linda M. Liau |
director |
120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075 |
| Mazin Sabra |
officer: Chief Operating Officer |
120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075 |
| Joseph Michael Burnett |
director, officer: CEO and President |
C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618 |
| L. Jeremy Stigall |
officer: GM, Biologics & Drug Delivery |
120 S. SIERRA AVENUE, SUITE 100, SOLANA BEACH CA 92075 |
| Danilo D'alessandro |
officer: Vice President, Finance |
5 MUSICK, IRVINE CA 92618 |
| Harold A Hurwitz |
officer: Chief Financial Officer |
|
| R John Fletcher |
director |
C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070 |
| Girin Pascal E R |
director |
C/O MRI INTERVENTIONS, INC., 5 MUSICK, IRVINE CA 92618 |
| B Kristine Johnson |
director |
366 FERNDALE RD S, WAYZATA MN 55391 |
| Timothy T. Richards |
director |
ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103 |
| Matthew B. Klein |
director |
C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
| Marcio Souza |
director |
C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080 |
| Voyager Therapeutics, Inc. |
10 percent owner |
75 HAYDEN AVENUE, LEXINGTON MA 02421 |
| Wendelin C Maners |
officer: Vice President, Marketing |
ONE COMMERCE SQUARE, SUITE 2550, MEMPHIS TN 38103 |
ClearPoint Neuro (ClearPoint Neuro) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CLPT has been successfully added to your 